Publications

Filters: Author is Ivanova, Anastasia and First Letter Of Keyword is D  [Clear All Filters]
2015
Song, Guochen, and Anastasia Ivanova. "Enrollment and Stopping Rules for Managing Toxicity Requiring Long Follow-Up in Phase II Oncology Trials." J Biopharm Stat 25, no. 6 (2015): 1206-14.
2016
Ivanova, Anastasia, Barry Paul, Olga Marchenko, Guochen Song, Neerali Patel, and Stergios J. Moschos. "Nine-year change in statistical design, profile, and success rates of Phase II oncology trials." J Biopharm Stat 26, no. 1 (2016): 141-9.
Wages, Nolan A., Anastasia Ivanova, and Olga Marchenko. "Practical designs for Phase I combination studies in oncology." J Biopharm Stat 26, no. 1 (2016): 150-66.
Ivanova, Anastasia, Yunfei Wang, and Matthew C. Foster. "The rapid enrollment design for Phase I clinical trials." Stat Med 35, no. 15 (2016): 2516-24.
2017
Chiuzan, Cody, Jonathan Shtaynberger, Gulam A. Manji, Jimmy K. Duong, Gary K. Schwartz, Anastasia Ivanova, and Shing M. Lee. "Dose-finding designs for trials of molecularly targeted agents and immunotherapies." J Biopharm Stat 27, no. 3 (2017): 477-494.
Jia, Xiaoyu, Anastasia Ivanova, and Shing M. Lee. "Selection of the initial design for the two-stage continual reassessment method." J Biopharm Stat 27, no. 3 (2017): 495-506.
2019
Bayar, Mohamed Amine, Anastasia Ivanova, and Gwenael Le Teuff. "CRM2DIM: A SAS macro for implementing the dual-agent Bayesian continual reassessment method." Comput Methods Programs Biomed 176 (2019): 211-223.
Bayar, Mohamed Amine, Anastasia Ivanova, and Gwenael Le Teuff. "CRM2DIM: A SAS macro for implementing the dual-agent Bayesian continual reassessment method." Comput Methods Programs Biomed 176 (2019): 211-223.
Xue, Xiaoqiang, Matthew C. Foster, and Anastasia Ivanova. "Rapid enrollment design for finding the optimal dose in immunotherapy trials with ordered groups." J Biopharm Stat 29, no. 4 (2019): 625-634.
2020
Li, Xiang, Anastasia Ivanova, Hong Tian, Pilar Lim, and Kevin Liu. "Continual reassessment method with regularization in phase I clinical trials." J Biopharm Stat 30, no. 6 (2020): 964-978.